ClinicalTrials.gg
RecruitingNCT07941817Updated Nov 17, 2026

Using Narrative Exposure Therapy to Treat Violent Offenders With Post Traumatic Stress and Emotion Dysregulation.

An interventional study of Narrative Exposure Therapy in PTSD - Post Traumatic Stress Disorder, CPTSD, Compelx Post-traumatic Stress Disorder and Emotion Dysregulation, sponsored by University of Lincoln. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by University of Lincoln · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Jun 2026, registered Nov 2026).
  • Started Jun 2026; still recruiting 4 months later.
Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to find out whether a therapy called Narrative Exposure Therapy (NET) is suitable and could be helpful for people who:

  • have experienced trauma
  • find it hard to manage their emotions
  • have a history of violent offending

NET is already used in clinical practice, but there is limited research about how helpful it is for this group. This study will look at whether NET:

  • is feasible to use in this population
  • reduces symptoms of post-traumatic stress (such as nightmares, flashbacks, and feeling on edge)
  • helps people manage their emotions better What is NET? NET is a one-to-one talking therapy for people who have experienced trauma. In NET, the patient and the therapist create a timeline of your life. This includes both positive experiences and difficult or traumatic events. individuals then talk through the traumatic events in a safe and structured way, with support from the therapist.

The aim is to help the brain process these memories so they cause less distress in everyday life. NET focuses on you as a whole person, not just on your offending history.

Read the detailed description

Trauma, emotion regulation and offending Individuals within the offending population have experienced more adverse childhood experiences (ACE's) and traumatic life events than those within the general population, indicating that experiences of post-traumatic stress may be more prevalent within this group when compared to the prevalence in the general population. Despite this, diagnosis of Post Traumatic Stress Disorder often goes undiagnosed and untreated within the offending population.

Emotion Regulation is defined as the ability to inhibit and maintain emotional expressions. ICD - 11 indicates for a diagnosis for Complex Post Traumatic Stress Disorder there should be difficulties in emotion regulation present . This is further evidenced by Cloitre et.al. who indicated that Adverse Childhood Experiences and prolonged trauma in childhood may lead to difficulties in emotion regulation. Thus, if levels of ACE's and traumatic life events are more prevalent in offending populations, this may indicate potential difficulties in emotion regulation.

Post traumatic stress and Heart Rate Variability (HRV) Post Traumatic Stress is identified as a cluster of symptoms that are associated with the diagnosis of PTSD. These symptoms include intrusions such as flashbacks and nightmares, avoidance, changes in cognition and mood such as negative thoughts about self or the world and arousal and reactivity for example being easily startled or on edge. Despite the experience of post traumatic stress being common in offending populations, PTSD often goes undiagnosed.

HRV refers to the fluctuation of heart rate over a period and is used as a physiological marker of mental wellbeing. HRV reflects the balance of the sympathetic and parasympathetic systems held within the autonomic nervous system. An increase in anxiety is reflected in reduced HRV, which indicates an increase in heart rate meaning that the sympathetic and parasympathetic systems are in acting parsimoniously. The ICD-10 recognises increased arousal as a post traumatic stress symptom, indicating increases in anxiety are related to post traumatic stress, thus reduced HRV. Research has shown alterations in HRV among individuals with PTSD, specifically, PTSD has been associated with reduced HRV, similar to the findings with anxiety. The reduced HRV observed in PTSD patients may be a physiological manifestation of this heightened stress state that is associated with post-traumatic stress. Thus, measuring HRV is a sufficient way of measuring distress associated with post - traumatic stress via physiological symptomology which is less subjective.

What is Narrative Exposure Therapy? Narrative Exposure Therapy (NET) is a short-term specific trauma therapy recommended by the National Institute for Health and Care Excellence (NICE) for work with refugees. NET was developed based on experiences seen in refugees and victims of torture. The researchers found that developing a narrative timeline of the victim's trauma, helped reduce post-traumatic stress symptoms and increased hope. In NET, individuals talk through a chronological narrative timeline of their life experiences, with the aim to reconstruct fragmented trauma memories into coherent narrative memories that are contextualised in the time and space that they originally happened. This is achieved by tapping into the fear network, the cognitive, emotional and sensory bodily memories of the trauma and connecting these memories to the chronological time that they happened, allowing for processing of the trauma memory and a more coherent, less fragmented life story being formed. Patients are encouraged to relive the emotions felt by the memory whilst staying connected to the present thus reminding the patient that the feelings are because of the memory, making episodic links to "then" and "now" . Furthermore, NET also works on the process of habituation, which means exposing yourself to the trauma memory, not avoiding it. This allows individuals to change their beliefs about the trauma memory by learning that the anxiety they feel when exposed to the memory will reduce (Lord, 2023), thus they will habituate to the memory.

Previous Research in NET NET has an increasing evidence base across various populations and has gained support in its treatment for CPTSD. NET has been shown to be potentially effective in reducing post-traumatic stress in various populations including refugees, women who have experienced Interpersonal Violence and veterans. An adapted version of NET (FORNET) has been shown to be a superior treatment in improving PTSD, aggression and depression in child soldiers. Thus, research has indicated the use of NET may be appropriate for those who have experienced traumatic life events and have potentially committed violence within the past. There is little evidence supporting the use of non-adapted NET in adults who have offended, thus further research is needed to investigate whether NET would be helpful in this population.

NET has also been evidenced to have less attrition than other trauma therapies when working with individuals with complex trauma histories, and NET is seen as the superior treatment for these individuals, this suggests that NET may be beneficial for those with complex trauma such as ACE's and interpersonal childhood trauma, which is often seen in offending populations.

Rationale for study This research aims to inform the growing research base of using NET within various populations. The results of this research have implications for further research into using NET within this population, which could indicate other potential positive outcomes such as decreased reoffending and use of services, which would decrease burden on already overstretched services. Despite the lack of research into using Narrative Exposure Therapy within offending populations, the intervention is starting to be used in practice and therefore research into this area is important to inform evidence-based practice. Furthermore, a lot of treatment focus for offenders is on managing forensic risk and is not person centred, often leaving the individual feeling that what has happened to them is not important. Research suggests that post traumatic stress is a risk factor for violent behaviour, thus indicating that a focus on trauma rather than risk may be beneficial for those who have committed violent offences in reducing risk but also improving mental wellbeing. Moreover, as NET encourages a complete view of a person's timeline, not just highlighting negative events but positive life events too, this minimises the emphasis on solely negative life experiences. This allows individuals to consider positives parts of their lives, rather than just negative life events and trauma, which is often a difficulty experienced in forensic populations due to the nature of the population

The purpose of this investigation is to understand whether NET is feasible to use within the population of violent offenders. We aim to investigate this by looking at its impact on experiences of post - traumatic stress and ability to regulate emotion. We also aim to look at participant experiences of NET, to inform whether this intervention is acceptable to use in this population and is accessible for them. This knowledge would inform further investigations into the potential effectiveness of NET within this population.

02

Conditions studied

  • PTSD - Post Traumatic Stress Disorder
  • CPTSD, Compelx Post-traumatic Stress Disorder
  • Emotion Dysregulation
  • Post Traumatic Stress Symptoms

Keywords

  • Trauma Interventions
  • Narrative Exposure Therapy,
  • Offenders
  • Violent Offenders
  • trauma
  • emotion dysregulation
03

In context

Combat Disorders

203 studies on the registry are indexed under Combat Disorders; 92 are open to participants now.

This study's planned enrollment of 6 is below the median of 72 across 170 interventional studies indexed under Combat Disorders.

Browse Combat Disorders studies →

Lead sponsor

University of Lincoln is the lead sponsor of 26 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Over 18 years
  • Can communicate and understand English independently, in a way that would meet the B2 reference level in the CEFR global scale
  • Experiencing post-traumatic stress or diagnosed with PTSD
  • Has difficulties regulating emotions assessed as in clinical assessment from the Community Forensic Team
  • Have committed a violent offence which they have been charged with.

Exclusion criteria

Exclusion Criteria:

  • Anyone who is presenting as acutely unwell, or struggling with active suicidal ideation, with plans and intent. Due to the nature of the therapy as stated above, and exposure to memories of potentially traumatic life events, it would not be suitable to conduct the therapy with those presenting with active risk to self.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (estimated)

Study arms

  • Experimental
    Narrative Exposure Therapy Treatment

    Participants will receive narrative exposure therapy

    Other: Narrative Exposure Therapy

Interventions

  • OtherNarrative Exposure Therapy

    Narrative Exposure Therapy

06

What researchers measure

Primary outcomes

  1. International Trauma Questionnaire

    Trauma Questionnaire that is based on the ICD 11 criteria for PTSD diagnosis. It is a Likert scale with scores ranging from 0-5. The higher the score the more symptoms individuals have.

    Time frame: From enrolment to the end of treatment. 3 week baseline Phases starting from Week 1, and then administered weekly following this until the end of treatment. This will be up to 20 sessions.

Secondary outcomes

  1. Difficulties in Emotion Regulation Scale -16

    A measure of emotion regulation. It is a Likert scale indicating with scores from 0-5, with higher scores indicating more difficulties in emotion regulation.

    Time frame: Before intervention at week 2 of the baseline phase and after intervention on the final session which could be up to session 20.

  2. CORE-10

    A measure of general wellbeing. A likert scale with scores from 0-5 with higher scores indicating worse overall wellbeing and lower scores indicating better overall wellbeing

    Time frame: From enrolment to the end of treatment. 3 week baseline Phases starting from Week 1, and then administered weekly following this until the end of treatment. This will be up to 20 sessions.

  3. Heart Rate Variability

    Time frame: To be administered after the 3 week baseline Phases, when trauma processing commences, starting from Week 2 of the experimental phase, and then administered weekly following this until the end of treatment. This will be up to 20 sessions.

07

Study locations

1 of 1 sites recruiting
  • Community Forensic Team
    Lincoln, United Kingdom
    Recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Dec 2026, 5 months after the start.

Of 75 non-industry interventional studies with no phase under Combat Disorders, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 44. This study's planned 5 months is below that.

Counting every sponsor, half of 81 studies reached it within 25 months; a quarter within 12 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2026
First posted
Nov 17, 2026
StartActual
Jun 23, 2026
Primary completionEst.
Dec 18, 2026
CompletionEst.
Dec 18, 2026
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07941817
Lead sponsor
University of Lincoln
Collaborators
Lincolnshire Partnership NHS Foundation Trust
Responsible party
Sponsor
First posted
Nov 17, 2026
Start date
Jun 23, 2026
Primary completion
Dec 18, 2026 (estimated)
Completion
Dec 18, 2026 (estimated)
Last update
Nov 17, 2026

Study contacts

Rebecca Watson
Contact
29629374@students.lincoln.ac.uk
07727734021
Thomas Schroder, Professor
Contact
Thomas.Schroder@nottingham.ac.uk
Rebecca Watson
principal investigator · University of Lincoln

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion